Yao Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yao Lu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bruce F. O'HAra
Department of Biology, University of Kentucky, Lexington, KY 40508-0225, USA
1 shared publication Hanqi Feng
Machine Learning Department School of Computer Science Carnegie Mellon University Pittsburgh Pennsylvania USA
1 shared publication- Jing Di
Department of Pathology & Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA
1 shared publication - Jingjing Hu
Department of Pathology University of California San Diego San Diego California USA
1 shared publication - Lei Zhang
The Fourth Affiliated Hospital of China Medical University
1 shared publication - Weihao Zhang
Department of Thoracic Surgery The Fourth Affiliated Hospital of China Medical University Shenyang China
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77778
Global Burden and Temporal Trends of Early‐Onset Tracheal, Bronchial, and Lung Cancer: An Analysis of GLOBOCAN 2022 and GBD 2023 Data
Background Early‐onset tracheal, bronchial, and lung (EOTBL) cancer represents a distinct clinical entity. This study aimed to assess the global burden and temporal trends of EOTBL cancer, focusing on socioeconomic disparities, to inform global cancer control strategies. Methods Using GLOBOCAN 2022 and GBD 2023 data, we analyzed EOTBL cancer incidence, mortality, and attributable risk factors across distinct geographic regions and Human Development Index (HDI) tiers. Findings In 2022, EOTBL cancer caused 137,705 incident cases and 72,646 deaths globally. Eastern Asia showed the highest incidence. Socioeconomically, regions with a High HDI presented the highest incidence burden. However, the Medium‐ and Low‐HDI regions experienced disproportionately high mortality burden. The temporal trends in EOTBL cancer exhibited profound national heterogeneity, closely tied to geography, human development, and sex. Risk profiles varied drastically: active smoking remained the primary driver in countries like Russia, whereas ambient particulate matter pollution emerged as a major determinant in rapidly developing economies like China. Interpretation EOTBL cancer pattern exhibits notable disparities across sex, geographic regions, and HDI levels. Framing effective global policies requires moving beyond generalized interventions toward tailored, region‐specific public health strategies.
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77778
Open AccessGlobal Burden and Temporal Trends of Early‐Onset Tracheal, Bronchial, and Lung Cancer: An Analysis of GLOBOCAN 2022 and GBD 2023 Data
Background Early‐onset tracheal, bronchial, and lung (EOTBL) cancer represents a distinct clinical entity. This study aimed to assess the global burden and temporal trends of EOTBL cancer, focusing on socioeconomic disparities, to inform global cancer control strategies. Methods Using GLOBOCAN 2022 and GBD 2023 data, we analyzed EOTBL cancer incidence, mortality, and attributable risk factors across distinct geographic regions and Human Development Index (HDI) tiers. Findings In 2022, EOTBL cancer caused 137,705 incident cases and 72,646 deaths globally. Eastern Asia showed the highest incidence. Socioeconomically, regions with a High HDI presented the highest incidence burden. However, the Medium‐ and Low‐HDI regions experienced disproportionately high mortality burden. The temporal trends in EOTBL cancer exhibited profound national heterogeneity, closely tied to geography, human development, and sex. Risk profiles varied drastically: active smoking remained the primary driver in countries like Russia, whereas ambient particulate matter pollution emerged as a major determinant in rapidly developing economies like China. Interpretation EOTBL cancer pattern exhibits notable disparities across sex, geographic regions, and HDI levels. Framing effective global policies requires moving beyond generalized interventions toward tailored, region‐specific public health strategies.
- Open Access
- 1 June 2026
- Published by Universidad del Zulia in Investigación Clínica
- Vol. 67 (2) , 241
Orientin attenuates pulmonary fibrosis via TGF-β1/suppressor of mother against decapentaplegic 3 (Smad3) pathway.
Orientin, a natural flavonoid found in many medicinal plants, can improve lung injury through anti-inflammatory and antioxidant effects, but its role in pulmonary fibrosis (PF) remains unstudied. Human Fetal Lung 1 (HFL1) cells were stimulated with transforming growth factor-β1 (TGF-β1), and a single intratracheal bleomycin instillation in mice was used to establish a PF mouse model. Orientin, the TGF-β1/suppressor of mother against decapentaplegic 3 (Smad3) pathway agonist SRI-011381, and the inhibitor SB431542 were used for intervention. The proliferation and migration were evaluated using the Cell Counting Kit-8 (CCK-8), Edu staining (evaluated proliferative activity) and a scratch-healing assay. Fibers in HFL1 cells were detected by Sirius red staining. Inflammation and fibrosis in lung tissue were assessed by pathological staining and enzyme-linked immunosorbent assay (ELISA). PF and TGF-β1/Smad3 path-way protein expressions were evaluated by Western blot. Orientin significantly reduced TGF-β1, p-Smad3, alpha-smooth muscle actin (α-SMA), Collagen I, and matrix metallopeptidase (MMP)-2 levels. After Orientin treatment, the Edu pos-itive cells, cell proliferation and migration were significantly reduced, and the number of red-stained collagen fibers was significantly reduced. After Orientin treatment, alveolar cavity collapse, inflammatory cell infiltration, and collagen fiber hyperplasia of mice were alleviated, and the contents of Hydroxyproline (HYP) and inflammatory factors in the alveolar lavage fluid were significantly reduced. SRI-011381 attenuated the effect of Orientin on the intervention, and inflammation and fibrosis levels were markedly increased. SB431542 enhanced the intervention effect of Orientin. Orientin inhibited TGF-β1/Smad3 signal-ing, inhibited fibroblast-to-myofibroblast transition (FMT) and extracellular matrix (ECM) production, and alleviated inflammatory and fibrotic damage.
- 1 June 2026
- Published by Universidad del Zulia in Investigación Clínica
- Vol. 67 (2) , 241
Open AccessOrientin attenuates pulmonary fibrosis via TGF-β1/suppressor of mother against decapentaplegic 3 (Smad3) pathway.
Orientin, a natural flavonoid found in many medicinal plants, can improve lung injury through anti-inflammatory and antioxidant effects, but its role in pulmonary fibrosis (PF) remains unstudied. Human Fetal Lung 1 (HFL1) cells were stimulated with transforming growth factor-β1 (TGF-β1), and a single intratracheal bleomycin instillation in mice was used to establish a PF mouse model. Orientin, the TGF-β1/suppressor of mother against decapentaplegic 3 (Smad3) pathway agonist SRI-011381, and the inhibitor SB431542 were used for intervention. The proliferation and migration were evaluated using the Cell Counting Kit-8 (CCK-8), Edu staining (evaluated proliferative activity) and a scratch-healing assay. Fibers in HFL1 cells were detected by Sirius red staining. Inflammation and fibrosis in lung tissue were assessed by pathological staining and enzyme-linked immunosorbent assay (ELISA). PF and TGF-β1/Smad3 path-way protein expressions were evaluated by Western blot. Orientin significantly reduced TGF-β1, p-Smad3, alpha-smooth muscle actin (α-SMA), Collagen I, and matrix metallopeptidase (MMP)-2 levels. After Orientin treatment, the Edu pos-itive cells, cell proliferation and migration were significantly reduced, and the number of red-stained collagen fibers was significantly reduced. After Orientin treatment, alveolar cavity collapse, inflammatory cell infiltration, and collagen fiber hyperplasia of mice were alleviated, and the contents of Hydroxyproline (HYP) and inflammatory factors in the alveolar lavage fluid were significantly reduced. SRI-011381 attenuated the effect of Orientin on the intervention, and inflammation and fibrosis levels were markedly increased. SB431542 enhanced the intervention effect of Orientin. Orientin inhibited TGF-β1/Smad3 signal-ing, inhibited fibroblast-to-myofibroblast transition (FMT) and extracellular matrix (ECM) production, and alleviated inflammatory and fibrotic damage.